Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" From Analysts
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" From Analysts
Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) has received a consensus rating of "Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $24.20.
據Marketbeat報道,泰莎基因療法公司(納斯達克代碼:TSHA-GET Rating)已經收到了目前報道該公司的11家研究公司的一致評級為“買入”。十位股票研究分析師已將該股評級為買入。在去年發佈了該股報告的經紀商中,1年期目標價平均為24.20美元。
Several brokerages have recently issued reports on TSHA. Chardan Capital reduced their price target on shares of Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Friday, August 12th. Guggenheim reduced their target price on shares of Taysha Gene Therapies to $22.00 and set a "na" rating on the stock in a report on Tuesday, May 17th. Needham & Company LLC reduced their target price on shares of Taysha Gene Therapies to $20.00 and set a "buy" rating on the stock in a report on Tuesday, May 17th. Wedbush reduced their target price on shares of Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating on the stock in a report on Friday, August 12th. Finally, The Goldman Sachs Group reduced their target price on shares of Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th.
幾家券商最近發佈了關於TSHA的報告。Chardan Capital在8月12日(星期五)的一份研究報告中將塔莎基因療法公司的股票目標價從34.00美元下調至32.00美元,並對該股設定了買入評級。古根海姆在5月17日(星期二)的一份報告中將塔莎基因療法公司的股票目標價下調至22.00美元,並將其股票評級定為“NA”。Needham&Company LLC在5月17日(星期二)的一份報告中將塔莎基因療法公司的股票目標價下調至20.00美元,並對該股設定了“買入”評級。韋德布什在8月12日(星期五)的一份報告中將塔莎基因療法公司的股票目標價從9.00美元下調至5.00美元,並對該股設定了“跑贏大盤”的評級。最後,高盛夫婦在5月24日(星期二)的一份報告中將塔莎基因治療公司的股票目標價從27.00美元下調至16.00美元,並對該股設定了“買入”評級。
Insider Activity at Taysha Gene Therapies
泰莎基因療法公司的內部活動
In related news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction on Friday, July 1st. The shares were sold at an average price of $3.53, for a total value of $84,448.19. Following the transaction, the chief marketing officer now directly owns 543,450 shares in the company, valued at approximately $1,918,378.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction on Friday, July 1st. The shares were sold at an average price of $3.53, for a total value of $84,448.19. Following the transaction, the chief marketing officer now directly owns 543,450 shares in the company, valued at approximately $1,918,378.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kamran Alam sold 9,717 shares of the business's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $3.50, for a total transaction of $34,009.50. Following the sale, the chief financial officer now owns 269,446 shares in the company, valued at $943,061. The disclosure for this sale can be found here. Insiders have sold a total of 57,345 shares of company stock worth $208,051 in the last three months. Insiders own 42.40% of the company's stock.
在相關新聞中,CMO Suyash Prasad在7月1日星期五的一筆交易中出售了23,923股泰莎基因療法的股票。這些股票的平均價格為3.53美元,總價值為84,448.19美元。交易完成後,首席營銷官現在直接持有該公司543,450股票,價值約1,918,378.50美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過這個鏈接訪問。在相關新聞中,CMO Suyash Prasad在7月1日星期五的一筆交易中出售了23,923股泰莎基因療法的股票。這些股票的平均價格為3.53美元,總價值為84,448.19美元。交易完成後,首席營銷官現在直接持有該公司543,450股票,價值約1,918,378.50美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過這個鏈接訪問。此外,首席財務官卡姆蘭·阿拉姆在8月22日星期一的一次交易中出售了9,717股該公司的股票。該股以3.50美元的平均價格出售,總成交金額為34,009.50美元。出售後,這位首席財務官現在擁有該公司269,446股,價值943,061美元。此次拍賣的披露信息可在此處找到。過去三個月,內部人士總共出售了57,345股公司股票,價值208,051美元。內部人士持有該公司42.40%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
Taysha Gene Therapies Stock Up 11.4 %
泰莎基因療法股票上漲11.4%
Shares of TSHA opened at $3.42 on Monday. The stock has a market capitalization of $140.54 million, a PE ratio of -0.71 and a beta of 1.09. Taysha Gene Therapies has a 1 year low of $2.33 and a 1 year high of $21.29. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.79 and a current ratio of 1.79. The company's 50-day simple moving average is $3.96 and its 200-day simple moving average is $4.37.
週一,TSHA的股價開盤報3.42美元。該股市值為1.4054億美元,市盈率為-0.71,貝塔係數為1.09。泰莎基因療法的一年低點為2.33美元,一年高位為21.29美元。該公司的負債權益比率為1.15,速動比率為1.79,流動比率為1.79。該公司的50日簡單移動均線切入位為3.96美元,200日簡單移動均線切入位為4.37美元。
About Taysha Gene Therapies
關於塔莎基因療法
(Get Rating)
(獲取評級)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
泰莎基因療法公司是一家基因治療公司,專注於開發基於腺相關病毒的基因療法並將其商業化,用於治療中樞神經系統單基因疾病。它主要開發用於治療巨大軸索性神經病的TSHA-120;用於治療Rett綜合徵的TSHA-102;用於治療CLN1疾病的TSHA-121;用於治療CLN1疾病的TSHA-118;用於治療SLC13A5缺乏症的TSHA-105;以及用於治療GM2神經節苷脂缺乏的TSHA-101。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免費獲取StockNews.com關於塔莎基因療法的研究報告(TSHA)
- 電子藝界能扭轉電子遊戲市場的低迷嗎?
- 美元將軍是美國小池塘裏的大魚。
- 以下是CPI報告將決定市場底部的原因
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《泰莎基因療法日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對塔莎基因療法和相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。